Table 1.
Detailed clinical characteristics of the subjects
| Variables | MG | HC | p a) |
|---|---|---|---|
| Sample Size | 70 | 74 | – |
| Female | 39 (55.7%) | 44 (59.4%) | 0.652 |
| Age—years a) | 46.12 ± 1.54 | 44.86 ± 1.94 | 0.571 |
| Duration of disease—years b) | 5.70 ± 0.79 | – | – |
| Thymic hyperplasia | 23 (32.8%) | – | – |
| History of respiratory crisis | 19 (27.1%) | – | – |
| Antibody test | 23 (32.8%) | – | – |
| Anti‐AChR antibody (+) | 15 (21.4%) | – | – |
| Immunosuppressive treatment | 31 (44.3%) | – | – |
| Osserman classification | |||
| I | 31 (44.3%) | – | – |
| IIa | 18 (25.7%) | – | – |
| IIb | 21 (30.0%) | – | – |
| QMG c) | 4.19 ± 0.55b) | – | – |
a)
Two‐tailed student test for continuous variables (age), Chi‐square analyses for categorical variables (sex)
b)
Values are expressed as the mean ± standard error of mean
c)
Quantitative Myasthenia Gravis (QMG) test, QMG scores range from 0 to 39
Abbreviations: MG, myasthenia gravis; HC, healthy control.